Dear Ms. Kummerer:

Please refer to your Supplemental New Drug Applications (sNDA) dated July 20, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ritalin (methylphenidate hydrochloride) 5mg, 10mg, 20mg Tablets (NDA 10187); Ritalin SR (methylphenidate hydrochloride) 20mg Extended-Release Tablets (NDA 18029); and Ritalin LA (methylphenidate hydrochloride) 10mg, 20mg, 30mg, 40mg Extended-Release Capsules (NDA 21284).

We acknowledge receipt of your amendment dated May 15, 2013.

Reference is also made to an Agency letter dated June 20, 2012, informing you that the Agency identified cases suggestive of an association between the use of stimulants used for the treatment of Attention Deficit Hyperactivity Disorder and peripheral vascular vasculopathy, including Raynaud’s phenomenon, and requesting revisions to your product labeling.

These supplemental new drug applications propose the following revisions to product labeling.

1. Addition of a new subsection under **Warnings** entitled **Peripheral Vasculopathy, including Raynaud’s phenomenon**.
2. Addition of a new subsection under **Precautions-Information for Patients** entitled *Circulation problems in fingers and toes [Peripheral vasculopathy, including Raynaud’s phenomenon]*.
3. Revisions to the Medication Guide relating to peripheral vasculopathy, including Raynaud’s phenomenon.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Hiren Patel, Regulatory Project Manager, at (301) 796-2087.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director (acting)
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
06/07/2013